Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 6/20 | 0.45 |
| ▸ | PTPN12 | Q05209 | 3/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.45 |
| ▸ | PTPN13 | Q12923 | 2/20 | 0.45 |
| ▸ | SSU72 | Q9NP77 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619014 | 1.00 | SRC (0.70) | SRCPTPN1PTPN6PTPN11ALDH1A1 | |
| SCHEMBL4749781 | 0.83 | SRC (0.53) | SRCEPHX1CYP2D6CYP2C19CA12 | |
| SCHEMBL20869602 | 0.83 | SRC (1.00) | SRCPTPN1PTPN6PTPN11ALDH1A1 | |
| SCHEMBL9912818 | 0.83 | SRC (1.00) | SRCPTPN1PTPN6PTPN11ALDH1A1 | |
| SCHEMBL11166146 | 0.83 | SRC (1.00) | SRCPTPN1PTPN6PTPN11ALDH1A1 | |
| SCHEMBL11764038 | 0.82 | SRC (0.62) | SRCPTPN1PTPN6PTPN11ALDH1A1 | |
| SCHEMBL3514146 | 0.82 | SRC (0.52) | SRCEPHX1CYP2D6CYP2C19 | |
| SCHEMBL5153770 | 0.82 | SRC (0.52) | SRCEPHX1CYP2D6CYP2C19 | |
| SCHEMBL11211519 | 0.82 | SRC (0.69) | SRCPTPN1PTPN6PTPN11ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28043659 | 0.82 | SRC (0.52) | SRCEPHX1CYP2D6CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0005507-A1 | Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby | CIBA-GEIGY AG (CH) | 1979-11-28 | — | — | EP | claimed |
| CN-115297860-B | Novel N-aryl oxamic acids | 普渡研究基金会 | 2024-10-15 | — | — | CN | disclosed |
| EP-4132523-A1 | NOVEL N-ARYL OXAMIC ACIDS | Purdue Research Foundation (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115297860-A | Novel N-aryl-oxalamic acids | 普渡研究基金会 | 2022-11-04 | — | — | CN | disclosed |
| US-11192850-B2 | N-aryl oxamic acids | PURDUE RESEARCH FOUNDATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210309606-A1 | Novel N-aryl Oxamic Acids | PURDUE RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | US | disclosed |
| US-20180170861-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USED THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-21 | — | — | US | disclosed |
| US-20180170862-A1 | PROTEIN TYROSINE PHOSPHATASES OR SHP2 INHIBITORS AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-21 | — | — | US | disclosed |
| US-20180170862-A1 | PROTEIN TYROSINE PHOSPHATASES OR SHP2 INHIBITORS AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-21 | — | — | US | disclosed |
| US-20180170861-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USED THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-21 | — | — | US | disclosed |
| US-4068073-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
| US-4066761-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1978-01-03 | — | — | US | disclosed |
| US-4064242-A | ANTIBACTERIAL AGENTS | SMITHKLINE CORPORATION (US) | 1977-12-20 | — | — | US | disclosed |
| US-4059591-A | Ureidoalkyl substituted tetrazole thiol intermediates for preparing cephalosporins | SMITHKLINE CORPORATION (US) | 1977-11-22 | — | — | US | disclosed |
| US-4057631-A | CEPHALOSPORINS, BACTERICIDE | SMITHKLINE CORPORATION (US) | 1977-11-08 | — | — | US | disclosed |
| US-4048311-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4041162-A | ANTIBIOTICS, BACTERICIDES | SMITHKLINE CORPORATION (US) | 1977-08-09 | — | — | US | disclosed |
| US-4034092-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-07-05 | — | — | US | disclosed |
| US-4025626-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-05-24 | — | — | US | disclosed |
| US-3962232-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309606-A1 | Novel N-aryl Oxamic Acids | PTPRB, PTPRO, PTPRM | SRC 460/4885PTPN1 14/4885PTPN6 17/4885 |
| US-20180170861-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USED THEREOF | PTPA, EPM2A, PTPRA | SRC 201/4885PTPN1 33/4885PTPN6 28/4885 |
| US-20180170862-A1 | PROTEIN TYROSINE PHOSPHATASES OR SHP2 INHIBITORS AND USES THEREOF | PTPA, PTPRA, PTPRCAP | SRC 119/4885PTPN1 22/4885PTPN6 23/4885 |
| US-11192850-B2 | N-aryl oxamic acids | PTPRB, PTPRO, PTPRM | SRC 433/4885PTPN1 13/4885PTPN6 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.